Professor Tjalf Ziemssen

All Stories

Gait dysfunction as an early marker of phenoconversion in REM sleep behavior disorder

Article • Scientific Reports, February 2026, Springer Science + Business Media

Professor Tjalf Ziemssen
Preparatory Alpha-band Modulations of Directed Information Transfer in Frontoparietal Circuits Support Adaptive Behavior

Article • Journal of Cognitive Neuroscience, February 2026, The MIT Press

Professor Tjalf Ziemssen
Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist Interviews

Article • Journal of the Neurological Sciences, February 2026, Elsevier

Professor Tjalf Ziemssen
Detecting progressing events in MS clinics in real-time is possible: No

Article • Multiple Sclerosis Journal, January 2026, SAGE Publications

Professor Tjalf Ziemssen
Digitale Neurologie

Article • January 2026, Elsevier

Professor Tjalf Ziemssen
Longitudinal high-frequency blood biomarkers of axonal injury and astrocytic activation after immune reconstitution in multiple sclerosis

Article • Journal of Neuroinflammation, December 2025, Springer Science + Business Media

Professor Tjalf Ziemssen
Elevated neurofilament light levels in acute anorexia nervosa are associated with alterations in white matter volume and connectivity networks

Article • Journal of Child Psychology and Psychiatry, December 2025, Wiley

Professor Tjalf Ziemssen
Education Research: Can Large Language Models Match MS Specialist Training?

Article • Neurology Education, December 2025, Wolters Kluwer Health

Professor Tjalf Ziemssen
Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis

Article • Multiple Sclerosis Journal, October 2025, SAGE Publications

Professor Tjalf Ziemssen
Whole brain volume loss is associated with a short-term disability progression in relapse-activity free multiple sclerosis

Article • Deutsche Zeitschrift für Nervenheilkunde, October 2025, Springer Science + Business Media

Professor Tjalf Ziemssen
From implementation to discontinuation: multi-year experience with the multiple sclerosis performance test as a digital monitoring tool

Article • Frontiers in Digital Health, October 2025, Frontiers

Professor Tjalf Ziemssen
A Review of the Impact of Platform Therapies (DMTs) on Associated Clinical Symptoms of Multiple Sclerosis

Article • Journal of Multidisciplinary Healthcare, October 2025, Taylor & Francis

Professor Tjalf Ziemssen
Phenotyping and characterising gait profiles of people with multiple sclerosis

Article • Scientific Reports, September 2025, Springer Science + Business Media

Professor Tjalf Ziemssen
Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age‐ and BMI‐Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response

Article • Annals of Clinical and Translational Neurology, August 2025, Wiley

Professor Tjalf Ziemssen
Determinants of health literacy and its impact on illness perception in patients with multiple sclerosis: evidence from patient-reported outcomes

Article • BMJ Neurology Open, July 2025, BMJ

Professor Tjalf Ziemssen
Experiences of People with Multiple Sclerosis in Sensor-Based Jump Assessment

Article • Bioengineering, June 2025, MDPI AG

Professor Tjalf Ziemssen
Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study

Article • Multiple Sclerosis Journal, June 2025, SAGE Publications

Professor Tjalf Ziemssen
Diagnostic uncertainty in the era of biosimilar natalizumab—The case for harmonizing anti-JCV antibody testing

Article • Multiple Sclerosis Journal, June 2025, SAGE Publications

Professor Tjalf Ziemssen
CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany

Article • Frontiers in Neurology, May 2025, Frontiers

Professor Tjalf Ziemssen
A roadmap for safe, regulation-compliant Living Labs for AI and digital health development

Article • Science Advances, May 2025, American Association for the Advancement of Science

Professor Tjalf Ziemssen
RECLAIM—A retrospective, multicenter observational study aimed at enabling the development of artificial intelligence-driven prognostic models for disease progression in multiple sclerosis

Article • Frontiers in Neurology, May 2025, Frontiers

Professor Tjalf Ziemssen
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis

Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, May 2025, New England Journal of Medicine (NEJM/MMS)

Professor Tjalf Ziemssen
Serum glial fibrillary protein reflects early brain injury dynamics and cognitive changes after deep brain stimulation surgery

Article • Scientific Reports, May 2025, Springer Science + Business Media

Professor Tjalf Ziemssen
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study

Article • Multiple Sclerosis Journal, April 2025, SAGE Publications

Professor Tjalf Ziemssen
Variations in neuronal cytoskeletal integrity affect directed communication in distributed networks during inhibitory control

Article • Communications Biology, March 2025, Springer Science + Business Media

Professor Tjalf Ziemssen
Patient Perspectives on Healthcare Utilization During the COVID-19 Pandemic in People with Multiple Sclerosis—A Longitudinal Analysis

Article • Healthcare, March 2025, MDPI AG

Professor Tjalf Ziemssen
Editorial: Digital twins in medicine—transition from theoretical concept to tool used in everyday care

Article • Frontiers in Digital Health, February 2025, Frontiers

Professor Tjalf Ziemssen
Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs

Article • Pathogens, February 2025, MDPI AG

Professor Tjalf Ziemssen
Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS

Article • Neurology, February 2025, Wolters Kluwer Health

Professor Tjalf Ziemssen
Digital Representation of Patients as Medical Digital Twins: Data-Centric Viewpoint

Article • JMIR Medical Informatics, January 2025, JMIR Publications Inc.

Professor Tjalf Ziemssen
Cost–consequence analysis of early vs. delayed natalizumab use in highly active relapsing–remitting multiple sclerosis: a simulation study

Article • Deutsche Zeitschrift für Nervenheilkunde, January 2025, Springer Science + Business Media

Professor Tjalf Ziemssen
A plain language summary of a study exploring the experiences of people with relapsing–remitting multiple sclerosis: what symptoms and impacts of the disease matter most and how can they be evaluated better?

Article • Neurodegenerative Disease Management, January 2025, Taylor & Francis

Professor Tjalf Ziemssen
Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study

Article • Therapeutic Advances in Neurological Disorders, January 2025, SAGE Publications

Professor Tjalf Ziemssen
Multiple sclerosis treatment

Article • January 2025, Elsevier

Professor Tjalf Ziemssen
RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis

Article • Multiple Sclerosis and Related Disorders, January 2025, Elsevier

Professor Tjalf Ziemssen
Machine learning integration of MRI and gait reveals mobility phenotypes in multiple sclerosis

Article • Brain Communications, January 2025, Oxford University Press (OUP)

Professor Tjalf Ziemssen
Higher effect sizes for the detection of accelerated brain volume loss and disability progression in multiple sclerosis using deep-learning

Article • Computers in Biology and Medicine, December 2024, Elsevier

Professor Tjalf Ziemssen
Patients with relapsing-remitting multiple sclerosis show accelerated whole brain volume and thalamic volume loss early in disease

Article • Neuroradiology, November 2024, Springer Science + Business Media

Professor Tjalf Ziemssen
Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice

Article • Multiple Sclerosis Journal, November 2024, SAGE Publications

Professor Tjalf Ziemssen
MS brain health quality standards: a survey on the reality in clinical practice in Germany

Article • Neurological Research and Practice, November 2024, Springer Science + Business Media

Professor Tjalf Ziemssen
Eculizumab Use in Neuromyelitis Optica Spectrum Disorders

Article • Neurology, November 2024, Wolters Kluwer Health

Professor Tjalf Ziemssen
Funktionelle Elektrostimulation zur Versorgung bei paretischen Gangstörungen: Fokus auf Fußheberschwäche bei Multipler Sklerose

Article • neuroreha, November 2024, Thieme Publishing Group

Professor Tjalf Ziemssen
A 2-stage model of heterogenous treatment effects for brain atrophy in multiple sclerosis utilizing the MS PATHS research network

Article • Multiple Sclerosis and Related Disorders, November 2024, Elsevier

Professor Tjalf Ziemssen
Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study

Article • Journal of Central Nervous System Disease, October 2024, SAGE Publications

Professor Tjalf Ziemssen
Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons

Article • Journal of Comparative Effectiveness Research, October 2024, Becaris Publishing Limited

Professor Tjalf Ziemssen
Evaluation of therapy satisfaction with cladribine tablets in patients with RMS: Final results of the non-interventional study CLEVER

Article • Multiple Sclerosis and Related Disorders, October 2024, Elsevier

Professor Tjalf Ziemssen
Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study

Article • Clinical Epidemiology, October 2024, Taylor & Francis

Professor Tjalf Ziemssen
Neurological complications in oncology and their monitoring and management in clinical practice: a narrative review

Article • Supportive Care in Cancer, September 2024, Springer Science + Business Media

Professor Tjalf Ziemssen
Integrating large language models in care, research, and education in multiple sclerosis management

Article • Multiple Sclerosis Journal, September 2024, SAGE Publications

Professor Tjalf Ziemssen
Long-term effects of siponimod on cardiovascular and autonomic nervous system in secondary progressive multiple sclerosis

Article • Frontiers in Pharmacology, September 2024, Frontiers

Professor Tjalf Ziemssen
Detecting fatigue in multiple sclerosis through automatic speech analysis

Article • Frontiers in Human Neuroscience, September 2024, Frontiers

Professor Tjalf Ziemssen
Serum neurofilament light chain as a sensitive biomarker for neuromonitoring during extracorporeal membrane oxygenation

Article • Scientific Reports, September 2024, Springer Science + Business Media

Professor Tjalf Ziemssen
Raman Spectroscopy of Optically Trapped Living Human T Cell Subsets and Monocytes

Article • International Journal of Molecular Sciences, September 2024, MDPI AG

Professor Tjalf Ziemssen
COVID-19 and multiple sclerosis: challenges and lessons for patient care

Article • The Lancet Regional Health - Europe, September 2024, Elsevier

Professor Tjalf Ziemssen
ECTRIMS 2024 – ePoster

Article • Multiple Sclerosis Journal, September 2024, SAGE Publications

Professor Tjalf Ziemssen, Teaching Assistant, MD, PhD, Child neurologist Blažo Nikolić
ECTRIMS 2024 – Poster

Article • Multiple Sclerosis Journal, September 2024, SAGE Publications

Professor Tjalf Ziemssen
A future of AI-driven personalized care for people with multiple sclerosis

Article • Frontiers in Immunology, August 2024, Frontiers

Professor Tjalf Ziemssen
Correction: Ziemssen et al. Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC). Vaccines 2023, 11, 1374

Article • Vaccines, August 2024, MDPI AG

Professor Tjalf Ziemssen
Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis

Article • Multiple Sclerosis and Related Disorders, August 2024, Elsevier

Professor Tjalf Ziemssen
Using machine learning algorithms to detect fear of falling in people with multiple sclerosis in standardized gait analysis

Article • Multiple Sclerosis and Related Disorders, August 2024, Elsevier

Professor Tjalf Ziemssen
Rule-Based DSL for Continuous Features and ML Models Selection in Multiple Sclerosis Research

Article • Applied Sciences, July 2024, MDPI AG

Professor Tjalf Ziemssen
Challenges in monitoring the quality of care in multiple sclerosis—authors' reply

Article • The Lancet Regional Health - Europe, July 2024, Elsevier

Professor Tjalf Ziemssen
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study

Article • Neurology and Therapy, June 2024, Springer Science + Business Media

Professor Tjalf Ziemssen
SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma

Article • Vaccines, June 2024, MDPI AG

Professor Tjalf Ziemssen
Corticosteroid-depending effects on peripheral immune cell subsets vary according to disease modifying strategies in multiple sclerosis

Article • Frontiers in Immunology, June 2024, Frontiers

Professor Tjalf Ziemssen
Consensus quality indicators for monitoring multiple sclerosis

Article • The Lancet Regional Health - Europe, May 2024, Elsevier

Professor Tjalf Ziemssen
Escalating to medium‐ versus high‐efficacy disease modifying therapy after low‐efficacy treatment in relapsing remitting multiple sclerosis

Article • Brain and Behavior, April 2024, Wiley

Professor Tjalf Ziemssen
The Association of Age, Sex, and BMI on Lower Limb Neuromuscular and Muscle Mechanical Function in People with Multiple Sclerosis

Article • Biomedicines, April 2024, MDPI AG

Professor Tjalf Ziemssen
Sensitive Identification of Asymmetries and Neuromuscular Deficits in Lower Limb Function in Early Multiple Sclerosis

Article • Neurorehabilitation and Neural Repair, April 2024, SAGE Publications

Professor Tjalf Ziemssen
Neurofilaments as biomarkers in neurological disorders — towards clinical application

Article • Nature Reviews Neurology, April 2024, Springer Science + Business Media

Professor Fredrik Piehl, Professor Tjalf Ziemssen
Data on Ocrelizumab Treatment Collected by MS Patients in Germany Using Brisa App

Article • Journal of Personalized Medicine, April 2024, MDPI AG

Professor Tjalf Ziemssen
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis

Article • JAMA Neurology, April 2024, American Medical Association (AMA)

Professor Tjalf Ziemssen
Inhibitory control in WM gate-opening: Insights from alpha desynchronization and norepinephrine activity under atDCS stimulation

Article • NeuroImage, April 2024, Elsevier

Professor Tjalf Ziemssen
Optical coherence tomography as a potential surrogate marker of dopaminergic modulation across the life span

Article • Ageing Research Reviews, April 2024, Elsevier

Professor Tjalf Ziemssen
Toward mechanistic medical digital twins: some use cases in immunology

Article • Frontiers in Digital Health, March 2024, Frontiers

Professor Tjalf Ziemssen
Insights from Real-World Practice: The Dynamics of SARS-CoV-2 Infections and Vaccinations in a Large German Multiple Sclerosis Cohort

Article • Vaccines, March 2024, MDPI AG

Professor Tjalf Ziemssen
Use of machine learning algorithms to detect fear of falling in people with multiple sclerosis

Article • Clinical Neurophysiology, March 2024, Elsevier

Professor Tjalf Ziemssen
Forum on immune digital twins: a meeting report

Article • npj Systems Biology and Applications, February 2024, Springer Science + Business Media

Professor Tjalf Ziemssen
Building digital patient pathways for the management and treatment of multiple sclerosis

Article • Frontiers in Immunology, February 2024, Frontiers

Professor Tjalf Ziemssen
Effects of obstructive sleep apnea treatment on neurodegenerative biomarker neurofilament light chain and cognitive performance

Article • Journal of Sleep Research, February 2024, Wiley

Professor Tjalf Ziemssen
Understanding the Symptoms and Impacts Experienced by People with Relapsing–Remitting MS: A Qualitative Investigation Using Semi-Structured Interviews

Article • Neurology and Therapy, February 2024, Springer Science + Business Media

Trishna Bharadia, Professor Tjalf Ziemssen
Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab

Article • Human Vaccines & Immunotherapeutics, February 2024, Taylor & Francis

Professor Tjalf Ziemssen
Preferences, Adherence, and Satisfaction: Three Years of Treatment Experiences of People with Multiple Sclerosis

Article • Patient Preference and Adherence, February 2024, Taylor & Francis

Professor Tjalf Ziemssen
Repeated iv anti‐CD20 treatment in multiple sclerosis: Long‐term effects on peripheral immune cell subsets

Article • Annals of Clinical and Translational Neurology, January 2024, Wiley

Professor Tjalf Ziemssen
Serum neurofilament indicates accelerated neurodegeneration and predicts mortality in late-stage Parkinson’s disease

Article • npj Parkinson s Disease, January 2024, Springer Science + Business Media

Professor Tjalf Ziemssen
Comparison of time to clinically meaningful improvement in quality of life in neurological disorders in patients treated with natalizumab versus ocrelizumab

Article • Neurodegenerative Disease Management, January 2024, Taylor & Francis

Professor Tjalf Ziemssen
Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis – real-world evidence from Germany

Article • Therapeutic Advances in Neurological Disorders, January 2024, SAGE Publications

Professor Tjalf Ziemssen
Change from platform to high efficacy disease-modifying treatment for multiple sclerosis despite NEDA

Article • Neuroimmunology Reports, January 2024, Elsevier

Professor Tjalf Ziemssen
Neue Therapieansätze bei Multipler Sklerose inkl. Stellenwert älterer Präparate

Article • Fortschritte der Neurologie · Psychiatrie, January 2024, Thieme Publishing Group

Professor Tjalf Ziemssen
Polypharmacy in patients with multiple sclerosis and the impact on levels of care and therapy units

Article • Frontiers in Neurology, December 2023, Frontiers

Professor Tjalf Ziemssen
Claims-based algorithm to estimate the Expanded Disability Status Scale for multiple sclerosis in a German health insurance fund: a validation study using patient medical records

Article • Frontiers in Neurology, December 2023, Frontiers

Professor Tjalf Ziemssen
Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis

Article • Neurology, December 2023, Wolters Kluwer Health

Professor Tjalf Ziemssen
Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Article • Multiple Sclerosis Journal, October 2023, SAGE Publications

Professor Tjalf Ziemssen
Management of multiple sclerosis fatigue in the digital age: from assessment to treatment

Article • Frontiers in Neuroscience, October 2023, Frontiers

Professor Tjalf Ziemssen
MSMilan2023 – ePoster

Article • Multiple Sclerosis Journal, October 2023, SAGE Publications

Professor Tjalf Ziemssen
Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination

Article • Multiple Sclerosis Journal, September 2023, SAGE Publications

Professor Tjalf Ziemssen
MSMilan2023 – Paper Poster - Session 2

Article • Multiple Sclerosis Journal, September 2023, SAGE Publications

Professor Tjalf Ziemssen
MSMilan2023 – Paper Poster - Session 1

Article • Multiple Sclerosis Journal, September 2023, SAGE Publications

Professor Tjalf Ziemssen
The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis

Article • Current Medical Research and Opinion, September 2023, Taylor & Francis

Professor Tjalf Ziemssen
Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury

Article • Clinical Chemistry and Laboratory Medicine (CCLM), September 2023, De Gruyter

Professor Tjalf Ziemssen
Long-Term Immune Response Profiles to SARS-CoV-2 Vaccination and Infection in People with Multiple Sclerosis on Anti-CD20 Therapy

Article • Vaccines, September 2023, MDPI AG

Professor Tjalf Ziemssen
Zusammenhang von Neurofilament Light mit verringerter Kortexdicke in Anorexia nervosa

Article • Adipositas - Ursachen Folgeerkrankungen Therapie, September 2023, Thieme Publishing Group

Professor Tjalf Ziemssen
Neurofilaments – Small proteins of physiological significance and predictive power for future neurodegeneration and cognitive decline across the life span

Article • Ageing Research Reviews, September 2023, Elsevier

Professor Tjalf Ziemssen
Can ChatGPT explain it? Use of artificial intelligence in multiple sclerosis communication

Article • Neurological Research and Practice, August 2023, Springer Science + Business Media

Professor Tjalf Ziemssen
Influence of Pre-Analytic Conditions on Quantity of Lymphocytes

Article • International Journal of Molecular Sciences, August 2023, MDPI AG

Professor Tjalf Ziemssen
Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC)

Article • Vaccines, August 2023, MDPI AG

Professor Tjalf Ziemssen
Pilot study on the influence of acute alcohol exposure on biophysical parameters of leukocytes

Article • Frontiers in Molecular Biosciences, August 2023, Frontiers

Professor Tjalf Ziemssen
Classifying flow cytometry data using Bayesian analysis helps to distinguish ALS patients from healthy controls

Article • Frontiers in Immunology, August 2023, Frontiers

Professor Tjalf Ziemssen
Building a monitoring matrix for the management of multiple sclerosis

Article • Autoimmunity Reviews, August 2023, Elsevier

Professor Tjalf Ziemssen
NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines

Article • Frontiers in Immunology, July 2023, Frontiers

Professor Tjalf Ziemssen
Neue Therapieansätze bei Multipler Sklerose inkl. Stellenwert älterer Präparate

Article • Neurologie up2date, June 2023, Thieme Publishing Group

Professor Tjalf Ziemssen
Auricular Transcutaneous Vagus Nerve Stimulation Specifically Enhances Working Memory Gate Closing Mechanism: A System Neurophysiological Study

Article • Journal of Neuroscience, May 2023, Society for Neuroscience

Professor Tjalf Ziemssen
Influence of exercise on quantity and deformability of immune cells in multiple sclerosis

Article • Frontiers in Neurology, May 2023, Frontiers

Professor Tjalf Ziemssen
Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis

Article • Vaccines, May 2023, MDPI AG

Professor Tjalf Ziemssen
Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis

Article • CNS Drugs, May 2023, Springer Science + Business Media

Professor Tjalf Ziemssen
Immunotherapy: DIFFERENT SOURCES OF POLYOMAVIRUS-SPECIFIC T CELLS AS TREATMENT OPTION FOR JC POLYOMAVIRUS-TRIGGERED PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

Article • Cytotherapy, May 2023, Elsevier

Professor Tjalf Ziemssen
Serum neurofilament light concentrations are associated with cortical thinning in anorexia nervosa

Article • Psychological Medicine, March 2023, Cambridge University Press

Professor Tjalf Ziemssen
Countermovement Jumps Detect Subtle Motor Deficits in People with Multiple Sclerosis below the Clinical Threshold

Article • Biomedicines, March 2023, MDPI AG

Professor Tjalf Ziemssen
Data Resource Profile: The Multiple Sclerosis Documentation System 3D and AOK PLUS Linked Database (MSDS-AOK PLUS)

Article • Journal of Clinical Medicine, February 2023, MDPI AG

Professor Tjalf Ziemssen
The influence of the COVID-19 pandemic on the prescription of multiple sclerosis medication in Germany

Article • Biomedicine & Pharmacotherapy, February 2023, Elsevier

Professor Tjalf Ziemssen
Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity

Article • Proceedings of the National Academy of Sciences, January 2023, Proceedings of the National Academy of Sciences

Professor Tjalf Ziemssen
The chronic stress risk phenotype mirrored in the human retina as a neurodegenerative condition

Article • Stress, January 2023, Taylor & Francis

Amra Jujic, Roland von Känel, Professor Tjalf Ziemssen
Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis

Article • Digital Health, January 2023, SAGE Publications

Professor Tjalf Ziemssen
Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis

Article • Therapeutic Advances in Neurological Disorders, January 2023, SAGE Publications

Professor Tjalf Ziemssen
Driving time-based identification of gaps in specialised care coverage: An example of neuroinflammatory diseases in Germany

Article • Digital Health, January 2023, SAGE Publications

Professor Tjalf Ziemssen
Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline

Article • Therapeutic Advances in Neurological Disorders, January 2023, SAGE Publications

Professor Tjalf Ziemssen
Correlation and differences of patient-reported outcomes vs. Likert-Rating of MS symptoms in a real-world cohort using a digital patient app

Article • Digital Health, January 2023, SAGE Publications

Professor Tjalf Ziemssen
Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies

Article • Multiple Sclerosis Journal - Experimental Translational and Clinical, January 2023, SAGE Publications

Professor Tjalf Ziemssen
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

Article • Therapeutic Advances in Neurological Disorders, January 2023, SAGE Publications

Professor Tjalf Ziemssen
Secondary Progressive Multiple Sclerosis

Article • Neurology Neuroimmunology & Neuroinflammation, January 2023, Wolters Kluwer Health

Professor Tjalf Ziemssen
Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab

Article • Vaccines, December 2022, MDPI AG

Professor Tjalf Ziemssen
Erratum zu: Die Generation Alpha der Digital Health Innovationen – Eine Fallstudie aus der Multiple Sklerose Versorgung

Article • HMD Praxis der Wirtschaftsinformatik, December 2022, Springer Fachmedien Wiesbaden GmbH

Professor Tjalf Ziemssen
Associations ofsNfLwith clinico‐radiological measures in a largeMSpopulation

Article • Annals of Clinical and Translational Neurology, November 2022, Wiley

Professor Tjalf Ziemssen
Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients

Article • International Journal of Molecular Sciences, November 2022, MDPI AG

Professor Tjalf Ziemssen
Reader Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use

Article • Neurology, November 2022, Wolters Kluwer Health

Professor Tjalf Ziemssen
Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis

Article • Neurological Research and Practice, November 2022, Springer Science + Business Media

Professor Tjalf Ziemssen
Die Generation Alpha der Digital Health Innovationen – Eine Fallstudie aus der Multiple Sklerose Versorgung

Article • HMD Praxis der Wirtschaftsinformatik, November 2022, Springer Fachmedien Wiesbaden GmbH

Professor Tjalf Ziemssen
Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment

Article • Neurology Neuroimmunology & Neuroinflammation, November 2022, Wolters Kluwer Health

Professor Tjalf Ziemssen
Detection of Fall Risk in Multiple Sclerosis by Gait Analysis—An Innovative Approach Using Feature Selection Ensemble and Machine Learning Algorithms

Article • Brain Sciences, October 2022, MDPI AG

Professor Tjalf Ziemssen
Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients

Article • International Journal of Molecular Sciences, October 2022, MDPI AG

Professor Tjalf Ziemssen
Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more

Article • Expert Opinion on Drug Metabolism & Toxicology, October 2022, Taylor & Francis

Professor Tjalf Ziemssen
ECTRIMS 2022 – Poster

Article • Multiple Sclerosis Journal, October 2022, SAGE Publications

Professor Tjalf Ziemssen
Brain Atrophy Is Substantially Accelerated in Neurological Wilson's Disease: A Longitudinal Study

Article • Movement Disorders, September 2022, Wiley

Professor Tjalf Ziemssen
Serum neurofilament light chain and initial severity of neurological disease predict the early neurological deterioration in Wilson’s disease

Article • Acta Neurologica Belgica, September 2022, Springer Science + Business Media

Professor Tjalf Ziemssen
Rationale and design of the prevention of paclitaxel-related neurological side effects with lithium trial – Protocol of a multicenter, randomized, double-blind, placebo- controlled proof-of-concept phase-2 clinical trial

Article • Frontiers in Medicine, August 2022, Frontiers

Professor Tjalf Ziemssen
Evaluation der langfristigen klinischen und ökonomischen Auswirkungen einer Behandlung mit Ofatumumab gegenüber Dimethylfumarat und Glatirameracetat bei Patienten mit schubförmiger Multipler Sklerose aus gesellschaftlicher Sicht in Deutschland

Article • Nervenheilkunde, July 2022, Thieme Publishing Group

Professor Tjalf Ziemssen
MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression

Article • Journal of Clinical Medicine, July 2022, MDPI AG

Professor Tjalf Ziemssen
Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses

Article • Frontiers in Immunology, July 2022, Frontiers

Professor Tjalf Ziemssen
Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): Development of a globally applicable quality improvement tool

Article • Multiple Sclerosis Journal - Experimental Translational and Clinical, July 2022, SAGE Publications

Professor Tjalf Ziemssen
Demographic Patterns of MS Patients Using BRISA: An MS-Specific App in Germany

Article • Journal of Personalized Medicine, July 2022, MDPI AG

Professor Tjalf Ziemssen
Brain structure and neurocognitive function in two professional mountaineers during 35 days of severe normobaric hypoxia

Article • European Journal of Neurology, June 2022, Wiley

Professor Tjalf Ziemssen
OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany

Article • Frontiers in Neurology, June 2022, Frontiers

Professor Tjalf Ziemssen
Transparent Quality Optimization for Machine Learning-Based Regression in Neurology

Article • Journal of Personalized Medicine, May 2022, MDPI AG

Professor Tjalf Ziemssen
FastCAT Accelerates Absolute Quantification of Proteins Using Multiple Short Nonpurified Chimeric Standards

Article • Journal of Proteome Research, May 2022, American Chemical Society (ACS)

Professor Tjalf Ziemssen
Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study

Article • Frontiers in Neurology, May 2022, Frontiers

Professor Tjalf Ziemssen
Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety

Article • Wiener Medizinische Wochenschrift, April 2022, Springer Science + Business Media

Professor Tjalf Ziemssen
Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart® Injector: Results of the Prospective Cohort Study REBIFLECT

Article • Advances in Therapy, April 2022, Springer Science + Business Media

Professor Tjalf Ziemssen
Comprehensive proteomic profiling of serum extracellular vesicles in patients with colorectal liver metastases identifies a signature for non-invasive risk stratification and early-response evaluation

Article • Molecular Cancer, April 2022, Springer Science + Business Media

Professor Tjalf Ziemssen
Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials

Article • Frontiers in Immunology, March 2022, Frontiers

Professor Tjalf Ziemssen
Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study

Article • Brain Sciences, February 2022, MDPI AG

Professor Tjalf Ziemssen
Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations

Article • Movement Disorders, February 2022, Wiley

Professor Tjalf Ziemssen
Neuer Masterstudiengang: Multiple Sklerose Management

Article • Wiener Medizinische Wochenschrift, February 2022, Springer Science + Business Media

Professor Tjalf Ziemssen
A role of the norepinephrine system or effort in the interplay of different facets of inhibitory control

Article • Neuropsychologia, February 2022, Elsevier

Professor Tjalf Ziemssen
Serum neurofilament indicates that DBS surgery can cause neuronal damage whereas stimulation itself does not

Article • Scientific Reports, January 2022, Springer Science + Business Media

Professor Tjalf Ziemssen
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions

Article • Multiple Sclerosis Journal, January 2022, SAGE Publications

Professor Tjalf Ziemssen
Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany

Article • Deutsche Zeitschrift für Nervenheilkunde, January 2022, Springer Science + Business Media

Professor Tjalf Ziemssen
S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review

Article • Therapeutic Advances in Neurological Disorders, January 2022, SAGE Publications

Professor Tjalf Ziemssen
Exploring in vivo lesion myelination dynamics: Longitudinal Myelin Water Imaging in early Multiple Sclerosis

Article • NeuroImage Clinical, January 2022, Elsevier

Professor Tjalf Ziemssen
Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC)

Article • Therapeutic Advances in Neurological Disorders, January 2022, SAGE Publications

Professor Tjalf Ziemssen
Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany

Article • Multiple Sclerosis Journal - Experimental Translational and Clinical, January 2022, SAGE Publications

Professor Tjalf Ziemssen
Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE

Article • Therapeutic Advances in Neurological Disorders, January 2022, SAGE Publications

Professor Tjalf Ziemssen
The need for a strategic therapeutic approach: multiple sclerosis in check

Article • Therapeutic Advances in Chronic Disease, January 2022, SAGE Publications

Professor Tjalf Ziemssen
Time-On-Task Effects on Working Memory Gating Processes—A Role of Theta Synchronization and the Norepinephrine System

Article • Cerebral Cortex Communications, January 2022, Oxford University Press (OUP)

Professor Tjalf Ziemssen
eHealth-Lösungen für die MS

Article • January 2022, Elsevier

Professor Tjalf Ziemssen
Neural and glial damage markers in women after long-term weight-recovery from anorexia nervosa

Article • Psychoneuroendocrinology, January 2022, Elsevier

Professor Tjalf Ziemssen
Digital Innovation in Multiple Sclerosis Management

Article • Brain Sciences, December 2021, MDPI AG

Professor Tjalf Ziemssen
Real-world Patient characteristics, Treatment Patterns and Costs in Relapsing Multiple Sclerosis Patients Treated With Glatiramer acetate, Dimethyl Fumarate Or Teriflunomide in Germany

Article • Neurodegenerative Disease Management, December 2021, Taylor & Francis

Professor Tjalf Ziemssen
Serum Neurofilament Light Chain: A Marker of Nervous System Damage in Myopathies

Article • Frontiers in Neuroscience, December 2021, Frontiers

Professor Tjalf Ziemssen
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

Article • Multiple Sclerosis Journal, December 2021, SAGE Publications

Professor Fredrik Piehl, Professor Tjalf Ziemssen
Daten sammeln aus der Praxis: der Weg zum digitalen MS-Zwilling

Article • DNP - Der Neurologe und Psychiater, December 2021, Springer Science + Business Media

Professor Tjalf Ziemssen
Digital Biomarkers in Multiple Sclerosis

Article • Brain Sciences, November 2021, MDPI AG

Professor Tjalf Ziemssen
Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects

Article • Cells, November 2021, MDPI AG

Professor Tjalf Ziemssen
Automated Analysis of the Two-Minute Walk Test in Clinical Practice Using Accelerometer Data

Article • Brain Sciences, November 2021, MDPI AG

Professor Tjalf Ziemssen
Cladribine Alters Immune Cell Surface Molecules for Adhesion and Costimulation: Further Insights to the Mode of Action in Multiple Sclerosis

Article • Cells, November 2021, MDPI AG

Professor Tjalf Ziemssen
The Multiple Sclerosis Data Alliance Catalogue

Article • International Journal of MS Care, November 2021, Consortium of Multiple Sclerosis Centers

Professor Tjalf Ziemssen
Cost of illness in multiple sclerosis by disease characteristics – A review of reviews

Article • Expert Review of Pharmacoeconomics & Outcomes Research, October 2021, Taylor & Francis

Professor Tjalf Ziemssen
Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey

Article • Journal of Medical Internet Research, October 2021, JMIR Publications Inc.

Professor Tjalf Ziemssen
Serum neurofilament light chain levels are associated with stroke severity and functional outcome in patients undergoing endovascular therapy for large vessel occlusion

Article • Journal of the Neurological Sciences, October 2021, Elsevier

Professor Tjalf Ziemssen
ECTRIMS 2021 – ePoster

Article • Multiple Sclerosis Journal, October 2021, SAGE Publications

Professor Tjalf Ziemssen
Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children

Article • Annals of Clinical and Translational Neurology, September 2021, Wiley

Professor Tjalf Ziemssen
Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation

Article • Frontiers in Immunology, August 2021, Frontiers

Professor Tjalf Ziemssen
Innovation in Digital Education: Lessons Learned from the Multiple Sclerosis Management Master’s Program

Article • Brain Sciences, August 2021, MDPI AG

Professor Tjalf Ziemssen
Profiles of eHealth Adoption in Persons with Multiple Sclerosis and Their Caregivers

Article • Brain Sciences, August 2021, MDPI AG

Professor Tjalf Ziemssen
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis

Article • Multiple Sclerosis Journal, August 2021, SAGE Publications

Professor Tjalf Ziemssen
Using Machine Learning Algorithms for Identifying Gait Parameters Suitable to Evaluate Subtle Changes in Gait in People with Multiple Sclerosis

Article • Brain Sciences, August 2021, MDPI AG

Professor Tjalf Ziemssen
Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions

Article • Neurological Research and Practice, August 2021, Springer Science + Business Media

Professor Tjalf Ziemssen
Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study

Article • Frontiers in Neurology, August 2021, Frontiers

Professor Tjalf Ziemssen
Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs

Article • International Journal of Molecular Sciences, July 2021, MDPI AG

Professor Tjalf Ziemssen
Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)

Article • Der Nervenarzt, July 2021, Springer Science + Business Media

Professor Tjalf Ziemssen
Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis

Article • Frontiers in Immunology, June 2021, Frontiers

Professor Tjalf Ziemssen
The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0

Article • Journal of Personalized Medicine, June 2021, MDPI AG

Professor Tjalf Ziemssen
Improving Digital Patient Care: Lessons Learned from Patient-Reported and Expert-Reported Experience Measures for the Clinical Practice of Multidimensional Walking Assessment

Article • Brain Sciences, June 2021, MDPI AG

Professor Tjalf Ziemssen
Der Multiple Sclerosis Health Resource Utilization Survey

Article • Fortschritte der Neurologie · Psychiatrie, May 2021, Thieme Publishing Group

Professor Tjalf Ziemssen
Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in a Rare Disease

Article • Journal of Personalized Medicine, May 2021, MDPI AG

Professor Tjalf Ziemssen
CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study

Article • Brain Pathology, May 2021, Wiley

Professor Tjalf Ziemssen
Digital Twins for Multiple Sclerosis

Article • Frontiers in Immunology, May 2021, Frontiers

Professor Tjalf Ziemssen
Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis

Article • Acta Neuropathologica Communications, May 2021, Springer Science + Business Media

Professor Tjalf Ziemssen
B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis

Article • Neurology Neuroimmunology & Neuroinflammation, May 2021, Wolters Kluwer Health

Professor Tjalf Ziemssen
CSF and Serum Biomarkers of Cerebral Damage in Autoimmune Epilepsy

Article • Frontiers in Neurology, April 2021, Frontiers

Professor Tjalf Ziemssen
Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis

Article • Frontiers in Neurology, April 2021, Frontiers

Professor Tjalf Ziemssen
Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey (Preprint)

Article • April 2021, JMIR Publications Inc.

Professor Tjalf Ziemssen
Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS

Article • Multiple Sclerosis Journal - Experimental Translational and Clinical, April 2021, SAGE Publications

Professor Tjalf Ziemssen
MSProDiscuss – Entwicklung eines digitalen Tools zur standardisierten Patientenanamnese, um Progredienz bei Multipler Sklerose zu identifizieren

Article • Fortschritte der Neurologie · Psychiatrie, March 2021, Thieme Publishing Group

Professor Tjalf Ziemssen
Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients

Article • Frontiers in Neurology, March 2021, Frontiers

Professor Tjalf Ziemssen
Delayed retinal vein recovery responses indicate both non-adaptation to stress as well as increased risk for stroke: the SABPA study

Article • CardioVascular Journal of Africa, February 2021, Clinics Cardive Publishing

Professor Tjalf Ziemssen
Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT® Autoinjector: A Prospective Observational Cohort Study

Article • Frontiers in Neurology, February 2021, Frontiers

Professor Tjalf Ziemssen
Differential longitudinal changes of neuronal and glial damage markers in anorexia nervosa after partial weight restoration

Article • Translational Psychiatry, February 2021, Springer Science + Business Media

Professor Tjalf Ziemssen
Dissonance in Music Impairs Spatial Gait Parameters in Patients with Parkinson’s Disease

Article • Journal of Parkinson’s Disease, February 2021, IOS Press

Professor Tjalf Ziemssen
Electronic Health Interventions in the Case of Multiple Sclerosis: From Theory to Practice

Article • Brain Sciences, February 2021, MDPI AG

Professor Tjalf Ziemssen
Serum biomarkers of cerebral cellular stress after self-limiting tonic clonic seizures: An exploratory study

Article • Seizure, February 2021, Elsevier

Professor Tjalf Ziemssen
Should We Use Clinical Tools to Identify Disease Progression?

Article • Frontiers in Neurology, January 2021, Frontiers

Professor Tjalf Ziemssen
Relation of retinal and hippocampal thickness in patients with amnestic mild cognitive impairment and healthy controls

Article • Brain and Behavior, January 2021, Wiley

Professor Tjalf Ziemssen
Impedimetric Microfluidic Sensor‐in‐a‐Tube for Label‐Free Immune Cell Analysis

Article • Small, January 2021, Wiley

Professor Tjalf Ziemssen
Fear of falling and falls in people with multiple sclerosis: A literature review

Article • Multiple Sclerosis and Related Disorders, January 2021, Elsevier

Professor Tjalf Ziemssen
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

Article • Therapeutic Advances in Neurological Disorders, January 2021, SAGE Publications

Professor Tjalf Ziemssen
Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study

Article • Therapeutic Advances in Neurological Disorders, January 2021, SAGE Publications

Professor Tjalf Ziemssen
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Article • Therapeutic Advances in Neurological Disorders, January 2021, SAGE Publications

Professor Tjalf Ziemssen
MSVirtual 2020 – Poster Abstracts

Article • Multiple Sclerosis Journal, December 2020, SAGE Publications

Professor Tjalf Ziemssen
Neurofilament light chain in serum is significantly increased in chorea-acanthocytosis

Article • Parkinsonism & Related Disorders, November 2020, Elsevier

Professor Tjalf Ziemssen
The Dresden Protocol for Multidimensional Walking Assessment (DMWA) in Clinical Practice

Article • Frontiers in Neuroscience, October 2020, Frontiers

Professor Tjalf Ziemssen
On the Reliability of Examining Dual-Tasking Abilities Using a Novel E-Health Device—A Proof of Concept Study in Multiple Sclerosis

Article • Journal of Clinical Medicine, October 2020, MDPI AG

Professor Tjalf Ziemssen
Chances and Challenges of Registry-Based Pharmacovigilance in Multiple Sclerosis: Lessons Learnt from the Implementation of the Multicenter REGIMS Registry

Article • Drug Safety, October 2020, Springer Science + Business Media

Professor Tjalf Ziemssen
Comparative study of microvascular function: Forearm blood flow versus dynamic retinal vessel analysis

Article • Clinical Physiology and Functional Imaging, October 2020, Wiley

Professor Tjalf Ziemssen
Long‐term peripheral immune cell profiling reveals further targets of oral cladribine in MS

Article • Annals of Clinical and Translational Neurology, October 2020, Wiley

Professor Tjalf Ziemssen
Der Patient als Experte

Article • DNP - Der Neurologe und Psychiater, October 2020, Springer Science + Business Media

Professor Tjalf Ziemssen
The role of TH17 cells in multiple sclerosis: Therapeutic implications

Article • Autoimmunity Reviews, October 2020, Elsevier

Professor Tjalf Ziemssen
Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years

Article • Multiple Sclerosis Journal - Experimental Translational and Clinical, October 2020, SAGE Publications

Professor Tjalf Ziemssen
The Transitional Phase of Multiple Sclerosis: The concept of PANGAEA 2.0 EVOLUTION Study

Article • Multiple Sclerosis and Related Disorders, September 2020, Elsevier

Professor Tjalf Ziemssen
Why Cognitive–Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice

Article • Frontiers in Neurology, August 2020, Frontiers

Professor Tjalf Ziemssen
Autoantibodies against central nervous system antigens in a subset of B cell–dominant multiple sclerosis patients

Article • Proceedings of the National Academy of Sciences, August 2020, Proceedings of the National Academy of Sciences

Professor Tjalf Ziemssen
A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose—Possible Predictors of Cardiac Outcomes

Article • Frontiers in Neurology, August 2020, Frontiers

Professor Tjalf Ziemssen
Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)

Article • Frontiers in Neurology, August 2020, Frontiers

Professor Tjalf Ziemssen
Ofatumumab versus Teriflunomide in Multiple Sclerosis

Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2020, New England Journal of Medicine (NEJM/MMS)

Dr Pedro Jesus Serrano-Castro, Dr. Ron Milo, Professor Tjalf Ziemssen
Patient‐ versus physician‐reported relapses in multiple sclerosis: insights from a large observational study

Article • European Journal of Neurology, August 2020, Wiley

Professor Tjalf Ziemssen
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

Article • CNS Drugs, July 2020, Springer Science + Business Media

Professor Tjalf Ziemssen
Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA

Article • JMIR Research Protocols, July 2020, JMIR Publications Inc.

Professor Tjalf Ziemssen
How to reduce the delay of diagnosing secondary progression in multiple sclerosis

Article • Multiple Sclerosis Journal, July 2020, SAGE Publications

Professor Tjalf Ziemssen
Interdisziplinäre Kommunikation: Augenarztbriefe an diabetologische Schwerpunktpraxen (DSP)

Article • Der Ophthalmologe, July 2020, Springer Science + Business Media

Professor Tjalf Ziemssen
A possible role of the norepinephrine system during sequential cognitive flexibility – Evidence from EEG and pupil diameter data

Article • Cortex, July 2020, Elsevier

Professor Tjalf Ziemssen
Data Collection in Multiple Sclerosis: The MSDS Approach

Article • Frontiers in Neurology, June 2020, Frontiers

Professor Tjalf Ziemssen
A Digital Patient Portal for Patients With Multiple Sclerosis

Article • Frontiers in Neurology, May 2020, Frontiers

Professor Tjalf Ziemssen
Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

Article • Neurology and Therapy, May 2020, Springer Science + Business Media

Professor Tjalf Ziemssen
Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration

Article • Frontiers in Neurology, May 2020, Frontiers

Professor Tjalf Ziemssen
Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis

Article • PharmacoEconomics, May 2020, Springer Science + Business Media

Professor Tjalf Ziemssen
Health-Related Quality of Life and the Relationship to Treatment Satisfaction in Patients with Multiple Sclerosis: Insights from a Large Observational Study

Article • Patient Preference and Adherence, May 2020, Taylor & Francis

Professor Tjalf Ziemssen
Clinical outcome measures in multiple sclerosis: A review

Article • Autoimmunity Reviews, May 2020, Elsevier

Professor Tjalf Ziemssen
Visual Feedback and Postural Control in Multiple Sclerosis

Article • Journal of Clinical Medicine, April 2020, MDPI AG

Professor Tjalf Ziemssen
Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA (Preprint)

Article • April 2020, JMIR Publications Inc.

Professor Tjalf Ziemssen
A Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm

Article • JMIR Medical Informatics, April 2020, JMIR Publications Inc.

Professor Tjalf Ziemssen
Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis

Article • Scientific Reports, April 2020, Springer Science + Business Media

Professor Tjalf Ziemssen
Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab

Article • Multiple Sclerosis and Related Disorders, April 2020, Elsevier

Professor Tjalf Ziemssen
Properties of lower level processing modulate the actions of the norepinephrine system during response inhibition

Article • Biological Psychology, April 2020, Elsevier

Professor Tjalf Ziemssen
Editorial: Cognitive Disorders in Neuroimmunological Diseases

Article • Frontiers in Neurology, March 2020, Frontiers

Professor Dawn Langdon, Professor Tjalf Ziemssen
The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study

Article • Journal of Medical Internet Research, March 2020, JMIR Publications Inc.

Professor Tjalf Ziemssen
Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts – the CONFIDENCE study protocol

Article • BMC Neurology, March 2020, Springer Science + Business Media

Professor Tjalf Ziemssen
Subcutaneous electrical stimulation in the treatment of facial pain due to multiple sclerosis

Article • Journal of Neurosurgery, March 2020, Journal of Neurosurgery Publishing Group (JNSPG)

Johann Klein, Professor Tjalf Ziemssen, Prof. Dr. med. Tareq A. Juratli
Balance Testing in Multiple Sclerosis—Improving Neurological Assessment With Static Posturography?

Article • Frontiers in Neurology, February 2020, Frontiers

Professor Tjalf Ziemssen
A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study

Article • Journal of Medical Internet Research, February 2020, JMIR Publications Inc.

Professor Tjalf Ziemssen
Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis

Article • Multiple Sclerosis and Related Disorders, February 2020, Elsevier

Professor Tjalf Ziemssen
How to Implement Adherence-Promoting Programs in Clinical Practice? A Discrete Choice Experiment on Physicians’ Preferences

Article • Patient Preference and Adherence, February 2020, Taylor & Francis

Professor Tjalf Ziemssen
A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians’ and patients’ views

Article • Multiple Sclerosis and Related Disorders, February 2020, Elsevier

Professor Tjalf Ziemssen
Antigen-shift in varicella-zoster virus-specific T-cell immunity over the course of Fingolimod-treatment in relapse-remitting multiple sclerosis patients

Article • Multiple Sclerosis and Related Disorders, February 2020, Elsevier

Professor Tjalf Ziemssen
Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis

Article • Frontiers in Immunology, January 2020, Frontiers

Professor Tjalf Ziemssen
The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study (Preprint)

Article • January 2020, JMIR Publications Inc.

Professor Tjalf Ziemssen
Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study

Article • CNS Drugs, January 2020, Springer Science + Business Media

Professor Tjalf Ziemssen
Correction to: Differentiating societal costs of disability worsening in multiple sclerosis

Article • Deutsche Zeitschrift für Nervenheilkunde, January 2020, Springer Science + Business Media

Professor Tjalf Ziemssen
Gender disparities in health resource utilization in patients with relapsing–remitting multiple sclerosis: a prospective longitudinal real-world study with more than 2000 patients

Article • Therapeutic Advances in Neurological Disorders, January 2020, SAGE Publications

Professor Tjalf Ziemssen
Differentiating societal costs of disability worsening in multiple sclerosis

Article • Deutsche Zeitschrift für Nervenheilkunde, December 2019, Springer Science + Business Media

Professor Tjalf Ziemssen
Metabolic and Non-Metabolic Peripheral Neuropathy: Is there a Place for Therapeutic Apheresis?

Article • Hormone and Metabolic Research, December 2019, Thieme Publishing Group

Professor Tjalf Ziemssen
Molecular biomarkers in multiple sclerosis

Article • Journal of Neuroinflammation, December 2019, Springer Science + Business Media

Professor Tjalf Ziemssen
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies

Article • Multiple Sclerosis Journal, November 2019, SAGE Publications

Professor Tjalf Ziemssen
Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Article • Multiple Sclerosis Journal, November 2019, SAGE Publications

Professor Tjalf Ziemssen
Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

Article • Multiple Sclerosis Journal, November 2019, SAGE Publications

Professor Tjalf Ziemssen
Kipptischuntersuchung – Schritt für Schritt

Article • Neurologie up2date, November 2019, Thieme Publishing Group

Professor Tjalf Ziemssen
Remote-Sensoring – neue Optionen des Progressionsmonitorings bei Multipler Sklerose

Article • Der Nervenarzt, October 2019, Springer Science + Business Media

Professor Tjalf Ziemssen
ECTRIMS 2019 – Oral Presentations

Article • Multiple Sclerosis Journal, September 2019, SAGE Publications

Professor Tjalf Ziemssen
ECTRIMS 2019 - Poster Session 1

Article • Multiple Sclerosis Journal, September 2019, SAGE Publications

Professor Tjalf Ziemssen
ECTRIMS 2019 - Poster Session 2

Article • Multiple Sclerosis Journal, September 2019, SAGE Publications

Professor Tjalf Ziemssen
ECTRIMS 2019 - Poster Session 3

Article • Multiple Sclerosis Journal, September 2019, SAGE Publications

Professor Tjalf Ziemssen
Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis

Article • Journal of Molecular Medicine, August 2019, Springer Science + Business Media

Professor Tjalf Ziemssen
Review: Patient-reported outcomes in multiple sclerosis care

Article • Multiple Sclerosis and Related Disorders, August 2019, Elsevier

Professor Tjalf Ziemssen
A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition

Article • Deutsche Zeitschrift für Nervenheilkunde, July 2019, Springer Science + Business Media

Professor Tjalf Ziemssen
Mutually reinforcing effects of genetic variants and interferon-β 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients

Article • July 2019, SAGE Publications

Professor Tjalf Ziemssen
Response to: Kobayashi et al.: “Erythroblast appearance associated with natalizumab” Multiple Sclerosis and Related Disorders 2019

Article • Multiple Sclerosis and Related Disorders, July 2019, Elsevier

Professor Tjalf Ziemssen
Early central vs. peripheral immunological and neurobiological effects of fingolimod—a longitudinal study

Article • Journal of Molecular Medicine, June 2019, Springer Science + Business Media

Professor Tjalf Ziemssen
How the depth of processing modulates emotional interference – evidence from EEG and pupil diameter data

Article • Cognitive Affective & Behavioral Neuroscience, June 2019, Springer Science + Business Media

Professor Tjalf Ziemssen
Response to Hyun J.W. et al. “Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis”

Article • Multiple Sclerosis Journal, May 2019, SAGE Publications

Professor Tjalf Ziemssen
Spectral Analysis of Heart Rate Variability: Time Window Matters

Article • Frontiers in Neurology, May 2019, Frontiers

Professor Tjalf Ziemssen
On the interrelation of 1/f neural noise and norepinephrine system activity during motor response inhibition

Article • Journal of Neurophysiology, May 2019, American Physiological Society

Professor Tjalf Ziemssen
Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS

Article • Neurology Neuroimmunology & Neuroinflammation, April 2019, Wolters Kluwer Health

Professor Tjalf Ziemssen
Letter to the editor regarding “Therapeutic drug monitoring of natalizumab”

Article • Multiple Sclerosis Journal, April 2019, SAGE Publications

Professor Tjalf Ziemssen
Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence

Article • Neurodegenerative Disease Management, April 2019, Future Medicine

Professor Tjalf Ziemssen
Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings

Article • Frontiers in Neurology, March 2019, Frontiers

Professor Tjalf Ziemssen
Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany

Article • Neurology Neuroimmunology & Neuroinflammation, March 2019, Wolters Kluwer Health

Professor Tjalf Ziemssen
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management

Article • Multiple Sclerosis Journal, February 2019, SAGE Publications

Professor Tjalf Ziemssen
The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System—A Review

Article • Frontiers in Neurology, February 2019, Frontiers

Professor Tjalf Ziemssen
Autonome Small-Fiber-Neuropathien

Article • Neurologie up2date, February 2019, Thieme Publishing Group

Professor Tjalf Ziemssen
Anodal tDCS affects neuromodulatory effects of the norepinephrine system on superior frontal theta activity during response inhibition

Article • Brain Structure and Function, January 2019, Springer Science + Business Media

Professor Tjalf Ziemssen
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

Article • JAMA, January 2019, American Medical Association (AMA)

Professor Tjalf Ziemssen
Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting

Article • Therapeutic Advances in Chronic Disease, January 2019, SAGE Publications

Professor Tjalf Ziemssen
Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies

Article • Journal of Central Nervous System Disease, January 2019, SAGE Publications

Professor Tjalf Ziemssen, Ute Essner
Exploring individual multiple sclerosis lesion volume change over time: Development of an algorithm for the analyses of longitudinal quantitative MRI measures

Article • NeuroImage Clinical, January 2019, Elsevier

Professor Tjalf Ziemssen
How minimal variations in neuronal cytoskeletal integrity modulate cognitive control

Article • NeuroImage, January 2019, Elsevier

Professor Tjalf Ziemssen
Multiple sclerosis registries in Europe – An updated mapping survey

Article • Multiple Sclerosis and Related Disorders, January 2019, Elsevier

Professor Tjalf Ziemssen
Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis

Article • Therapeutic Advances in Neurological Disorders, January 2019, SAGE Publications

Professor Tjalf Ziemssen
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine

Article • CNS Drugs, December 2018, Springer Science + Business Media

Professor Tjalf Ziemssen
Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up

Article • Frontiers in Neurology, December 2018, Frontiers

Professor Tjalf Ziemssen
Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients

Article • Frontiers in Immunology, November 2018, Frontiers

Professor Tjalf Ziemssen
International consensus on quality standards for brain health-focused care in multiple sclerosis

Article • Multiple Sclerosis Journal, November 2018, SAGE Publications

Professor Tjalf Ziemssen, Professor Fredrik Piehl
Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks

Article • Neurology, October 2018, Wolters Kluwer Health

Professor Tjalf Ziemssen
Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential

Article • CNS Drugs, September 2018, Springer Science + Business Media

Professor Tjalf Ziemssen
Sudomotor Testing of Diabetes Polyneuropathy

Article • Frontiers in Neurology, September 2018, Frontiers

Professor Tjalf Ziemssen
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis

Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2018, New England Journal of Medicine (NEJM/MMS)

Professor Jasna Jancic, Professor Tjalf Ziemssen
Predictors of response to opicinumab in acute optic neuritis

Article • Annals of Clinical and Translational Neurology, August 2018, Wiley

Professor Tjalf Ziemssen
Wissensstand von Patienten und Gesundheitsberufen über Diabetes-bedingte Augenerkrankungen (Risikofaktoren, Früherkennung und Behandlung)

Article • Diabetologie und Stoffwechsel, June 2018, Thieme Publishing Group

Professor Tjalf Ziemssen
Comment on Y.D. Fragoso et al.: “Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod” Multiple Sclerosis and Related Disorders 2017

Article • Multiple Sclerosis and Related Disorders, May 2018, Elsevier

Professor Tjalf Ziemssen
Letter to the editor to the paper: “Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis”

Article • Multiple Sclerosis and Related Disorders, May 2018, Elsevier

Professor Tjalf Ziemssen
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Article • The Lancet Neurology, May 2018, Elsevier

Professor Tjalf Ziemssen
Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology

Article • Journal of Autoimmunity, March 2018, Elsevier

Professor Tjalf Ziemssen, Prof. Dr. Jens Pietzsch
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Article • The Lancet, March 2018, Elsevier

Professor Tjalf Ziemssen, prof aksel siva
Improving multiple sclerosis management and collecting safety information in the real world: the MSDS3D software approach

Article • Expert Opinion on Drug Safety, February 2018, Taylor & Francis

Professor Tjalf Ziemssen
Dual-Tasking in Multiple Sclerosis – Implications for a Cognitive Screening Instrument

Article • Frontiers in Human Neuroscience, January 2018, Frontiers

Professor Tjalf Ziemssen
An Innovative Technique to Assess Spontaneous Baroreflex Sensitivity with Short Data Segments: Multiple Trigonometric Regressive Spectral Analysis

Article • Frontiers in Physiology, January 2018, Frontiers

Professor Tjalf Ziemssen
Fatigue and Sleep in Multiple Sclerosis Patients: A Comparison of Self-Report and Performance-Based Measures

Article • Frontiers in Neurology, January 2018, Frontiers

Professor Tjalf Ziemssen
Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany

Article • Therapeutic Advances in Neurological Disorders, January 2018, SAGE Publications

Professor Tjalf Ziemssen
Multi-component relaxation in clinically isolated syndrome: Lesion myelination may predict multiple sclerosis conversion

Article • NeuroImage Clinical, January 2018, Elsevier

Henning Schmitz-Peiffer, Professor Tjalf Ziemssen
Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis

Article • Therapeutic Advances in Neurological Disorders, January 2018, SAGE Publications

Professor Tjalf Ziemssen
Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting

Article • Therapeutic Advances in Neurological Disorders, January 2018, SAGE Publications

Professor Tjalf Ziemssen
Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit–Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA

Article • Neurotherapeutics, December 2017, Springer Science + Business Media

Professor Tjalf Ziemssen
Determination of Seminal Concentration of Fingolimod and Fingolimod-Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod

Article • Clinical Pharmacology in Drug Development, December 2017, Wiley

Professor Tjalf Ziemssen
Perceptions on the value of bodily functions in multiple sclerosis

Article • Acta Neurologica Scandinavica, December 2017, Wiley

Professor Tjalf Ziemssen
The role of phasic norepinephrine modulations during task switching: evidence for specific effects in parietal areas

Article • Brain Structure and Function, October 2017, Springer Science + Business Media

Professor Tjalf Ziemssen
Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis

Article • Frontiers in Neuroscience, October 2017, Frontiers

Professor Tjalf Ziemssen
Autonomic Dysfunction in Wilson's Disease: A Comprehensive Evaluation during a 3-Year Follow Up

Article • Frontiers in Physiology, October 2017, Frontiers

Professor Tjalf Ziemssen
Response to: S. Sega-Jazbec et al.: “Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis” Multiple Sclerosis and Related Disorders 2017

Article • Multiple Sclerosis and Related Disorders, October 2017, Elsevier

Professor Tjalf Ziemssen
Umsetzung der Nationalen VersorgungsLeitlinie (NVL) zur Therapie des Diabetes mellitus Typ 2 in diabetologischen Schwerpunktpraxen

Article • Diabetes aktuell, October 2017, Thieme Publishing Group

Professor Tjalf Ziemssen
Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis

Article • Expert Opinion on Pharmacotherapy, September 2017, Taylor & Francis

Professor Tjalf Ziemssen
Umsetzung der Nationalen VersorgungsLeitlinie (NVL) zur Therapie des Diabetes mellitus Typ 2 in diabetologischen Schwerpunktpraxen

Article • DMW - Deutsche Medizinische Wochenschrift, September 2017, Thieme Publishing Group

Professor Tjalf Ziemssen
Natalizumab during pregnancy and lactation

Article • Multiple Sclerosis Journal, August 2017, SAGE Publications

Professor Tjalf Ziemssen
Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS

Article • Journal of Neuroinflammation, August 2017, Springer Science + Business Media

Professor Tjalf Ziemssen
Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion

Article • Expert Opinion on Pharmacotherapy, August 2017, Taylor & Francis

Professor Tjalf Ziemssen
Letter to the editor on the paper: “The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”

Article • Multiple Sclerosis Journal, August 2017, SAGE Publications

Professor Tjalf Ziemssen
Patients’ preferences for involvement in the decision-making process for treating diabetic retinopathy

Article • BMC Ophthalmology, August 2017, Springer Science + Business Media

Professor Tjalf Ziemssen
Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world

Article • Therapeutic Advances in Neurological Disorders, August 2017, SAGE Publications

Professor Tjalf Ziemssen
Real-world-Evidenz

Article • Der Nervenarzt, August 2017, Springer Science + Business Media

Professor Tjalf Ziemssen
Demands on response inhibition processes determine modulations of theta band activity in superior frontal areas and correlations with pupillometry – Implications for the norepinephrine system during inhibitory control

Article • NeuroImage, August 2017, Elsevier

Professor Tjalf Ziemssen
Subthalamic nucleus stimulation and levodopa modulate cardiovascular autonomic function in Parkinson’s disease

Article • Scientific Reports, August 2017, Nature

Professor Tjalf Ziemssen
Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?

Article • Multiple Sclerosis Journal, July 2017, SAGE Publications

Professor Tjalf Ziemssen
To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question

Article • Expert Review of Neurotherapeutics, June 2017, Taylor & Francis

Professor Tjalf Ziemssen, Dr Emanuele D'amico
Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL

Article • PLOS One, May 2017, PLOS

Professor Tjalf Ziemssen
ActiGait implantable drop foot stimulator in multiple sclerosis: a new indication

Article • Journal of Neurosurgery, May 2017, Journal of Neurosurgery Publishing Group (JNSPG)

Professor Tjalf Ziemssen
A self-sustained loop of inflammation-driven inhibition of beige adipogenesis in obesity

Article • Nature Immunology, April 2017, Springer Science + Business Media

Professor Tjalf Ziemssen
Multiple sclerosis in the real world: A systematic review of fingolimod as a case study

Article • Autoimmunity Reviews, April 2017, Elsevier

Professor Tjalf Ziemssen
The norepinephrine system shows information-content specific properties during cognitive control – Evidence from EEG and pupillary responses

Article • NeuroImage, April 2017, Elsevier

Professor Tjalf Ziemssen
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Article • The Lancet Neurology, April 2017, Elsevier

Professor Tjalf Ziemssen, Dr Tomas Kalincik
Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment

Article • BMC Neurology, March 2017, Springer Science + Business Media

Professor Tjalf Ziemssen
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial

Article • The Lancet Neurology, March 2017, Elsevier

Professor Tjalf Ziemssen
Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation

Article • Journal of Neuroinflammation, February 2017, Springer Science + Business Media

Professor Tjalf Ziemssen
Treatment optimization in multiple sclerosis: how do we apply emerging evidence?

Article • Expert Review of Clinical Immunology, February 2017, Taylor & Francis

Professor Tjalf Ziemssen
Adrenal medullary dysfunction as a feature of obesity

Article • International Journal of Obesity, February 2017, Springer Science + Business Media

Professor Tjalf Ziemssen
The norepinephrine system and its relevance for multi-component behavior

Article • NeuroImage, February 2017, Elsevier

Professor Tjalf Ziemssen
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, January 2017, New England Journal of Medicine (NEJM/MMS)

Dr Cristina M Ramo-Tello, Professor Tjalf Ziemssen
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, January 2017, New England Journal of Medicine (NEJM/MMS)

Professor Tjalf Ziemssen
Electrocardiographic assessments and cardiac events after fingolimod first dose – a comprehensive monitoring study

Article • BMC Neurology, January 2017, Springer Science + Business Media

Professor Tjalf Ziemssen
Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson’s Disease (CAPTURE PD): Protocol for a Multicenter Study

Article • Frontiers in Neurology, January 2017, Frontiers

Professor Tjalf Ziemssen
Long-term safety and tolerability of glatiramer acetate 20 mg in the treatment of relapsing forms of multiple sclerosis

Article • Expert Opinion on Drug Safety, December 2016, Taylor & Francis

Professor Tjalf Ziemssen
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Article • Neurology, October 2016, Wolters Kluwer Health

Dr David R Snydman, Professor Tjalf Ziemssen
Immunomodulatory treatments and cognition in MS

Article • Acta Neurologica Scandinavica, September 2016, Wiley

Professor Tjalf Ziemssen
Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis

Article • JAMA Neurology, September 2016, American Medical Association (AMA)

Professor Tjalf Ziemssen
The norepinephrine system affects specific neurophysiological subprocesses in the modulation of inhibitory control by working memory demands

Article • Human Brain Mapping, August 2016, Wiley

Professor Tjalf Ziemssen
Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod

Article • BMC Neurology, August 2016, Springer Science + Business Media

Professor Tjalf Ziemssen
Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach

Article • BMC Neurology, August 2016, Springer Science + Business Media

Professor Tjalf Ziemssen
Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)

Article • BMC Neurology, July 2016, Springer Science + Business Media

Professor Tjalf Ziemssen
Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab

Article • BMC Neurology, July 2016, Springer Science + Business Media

Professor Tjalf Ziemssen
Development of the multiple sclerosis (MS) early mobility impairment questionnaire (EMIQ)

Article • Deutsche Zeitschrift für Nervenheilkunde, July 2016, Springer Science + Business Media

Professor Tjalf Ziemssen
Hes3 expression in the adult mouse brain is regulated during demyelination and remyelination

Article • Brain Research, July 2016, Elsevier

Professor Tjalf Ziemssen
New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies

Article • Journal of Neuroinflammation, June 2016, Springer Science + Business Media

Professor Tjalf Ziemssen
The importance of collecting structured clinical information on multiple sclerosis

Article • BMC Medicine, May 2016, Springer Science + Business Media

Professor Tjalf Ziemssen
6-sulpho LacNAc+dendritic cells accumulate in various inflammatory, but not ischaemic conditions of the central nervous system

Article • Neuropathology and Applied Neurobiology, May 2016, Wiley

Professor Tjalf Ziemssen
Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation

Article • Proceedings of the National Academy of Sciences, May 2016, Proceedings of the National Academy of Sciences

Professor Tjalf Ziemssen
Laquinimod in the treatment of relapsing remitting multiple sclerosis

Article • Expert Opinion on Drug Metabolism & Toxicology, May 2016, Taylor & Francis

Professor Tjalf Ziemssen
Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS

Article • Neurology Neuroimmunology & Neuroinflammation, April 2016, Wolters Kluwer Health

Professor Tjalf Ziemssen
Comparison of baroreflex sensitivity estimated from ECG R–R and inter-systolic intervals obtained by finger plethysmography and radial tonometry

Article • Acta Neurovegetativa, March 2016, Springer Science + Business Media

Professor Tjalf Ziemssen
Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey

Article • Therapeutic Advances in Neurological Disorders, March 2016, SAGE Publications

Professor Tjalf Ziemssen
Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie

Article • Der Nervenarzt, February 2016, Springer Science + Business Media

Professor Tjalf Ziemssen
QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients

Article • Deutsche Zeitschrift für Nervenheilkunde, February 2016, Springer Science + Business Media

Professor Tjalf Ziemssen
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid

Article • Nature, February 2016, Nature

Professor Tjalf Ziemssen
Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol

Article • JMIR Research Protocols, February 2016, JMIR Publications Inc.

Professor Tjalf Ziemssen
Designing an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System

Article • Interactive Journal of Medical Research, January 2016, JMIR Publications Inc.

Professor Tjalf Ziemssen
Limited Time from the Diabetes Patients' Perspective: Need for Conversation with the Eye Specialist

Article • Ophthalmologica, January 2016, Karger Publishers

Professor Tjalf Ziemssen
Optimizing treatment success in multiple sclerosis

Article • Deutsche Zeitschrift für Nervenheilkunde, December 2015, Springer Science + Business Media

Professor Tjalf Ziemssen
Physician–patient communication skills: e-tools

Article • Neurodegenerative Disease Management, December 2015, Future Medicine

Professor Tjalf Ziemssen
Welchen Effekt hat das Washout bei der Umstellung von Natalizumab auf Fingolimod?

Article • InFo Neurologie + Psychiatrie, November 2015, Springer Science + Business Media

Professor Tjalf Ziemssen
Patient mit Small-Fiber-Neuropathie — das können Sie tun

Article • MMW - Fortschritte der Medizin, November 2015, Springer Science + Business Media

Professor Tjalf Ziemssen
Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™)

Article • Neurology and Therapy, October 2015, Springer Science + Business Media

Professor Tjalf Ziemssen
Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing–remitting multiple sclerosis converting to glatiramer acetate

Article • BMC Neurology, October 2015, Springer Science + Business Media

Professor Tjalf Ziemssen
Recognition and treatment of autonomic disturbances in Parkinson’s disease

Article • Expert Review of Neurotherapeutics, September 2015, Informa Healthcare

Professor Tjalf Ziemssen
Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review

Article • PLOS One, September 2015, PLOS

Professor Tjalf Ziemssen
Ein Jahr Alemtuzumab – was haben wir in der Praxis gelernt? Experten-Erfahrungsaustausch zur Therapie der Multiplen Sklerose

Article • Aktuelle Neurologie, September 2015, Thieme Publishing Group

Professor Tjalf Ziemssen
Optimizing therapy early in multiple sclerosis: An evidence-based view

Article • Multiple Sclerosis and Related Disorders, September 2015, Elsevier

Professor Tjalf Ziemssen
Local endothelial dysfunction does not affect global endothelial function

Article • VASA, July 2015, Hogrefe Publishing Group

Professor Tjalf Ziemssen
The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice

Article • BMC Neurology, June 2015, Springer Science + Business Media

Professor Tjalf Ziemssen
Insulin is a key determinant of elevated retinal arteriolar flicker response in insulin-resistant individuals

Article • Diabetologia, May 2015, Springer Science + Business Media

Professor Tjalf Ziemssen
Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone on Peripheral Vessel Function and Clinical Parameters in Nondiabetic Patients: A Double-Center, Randomized Controlled Pilot Trial

Article • Cardiology, May 2015, Karger Publishers

Professor Tjalf Ziemssen
Acute hyperlipidemia but not hyperhomocysteinemia impairs reflex regulation of the cardiovascular system

Article • Atherosclerosis Supplements, May 2015, Elsevier

Professor Tjalf Ziemssen
Different responses of the retinal and cutaneous microcirculation to transient dysmetabolic conditions

Article • Atherosclerosis Supplements, May 2015, Elsevier

Professor Tjalf Ziemssen
Immunoadsorption with regenerating systems in neurological disorders – A single center experience

Article • Atherosclerosis Supplements, May 2015, Elsevier

Professor Tjalf Ziemssen
Brain Magnetic Resonance Imaging Findings Fail to Suspect Fabry Disease in Young Patients With an Acute Cerebrovascular Event

Article • Stroke, April 2015, Wolters Kluwer Health

Dr Stefan Ropele, Prof. Dr. Otto W. Witte, Professor Tjalf Ziemssen
Dynamic formation of macular microcysts independent of vitreous traction changes

Article • Neurology, January 2015, Wolters Kluwer Health

Professor Tjalf Ziemssen
MS-Dokumentation, MS-Register und MS-Management

Article • January 2015, Elsevier

Professor Tjalf Ziemssen
Metabolische Störungen

Article • January 2015, Springer Science + Business Media

Professor Tjalf Ziemssen
A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe

Article • Multiple Sclerosis and Related Disorders, January 2015, Elsevier

Professor Tjalf Ziemssen
Autorenverzeichnis

Article • January 2015, Elsevier

Professor Tjalf Ziemssen
Time for Change – Evolution of Real-world Evidence Outcome Measures in Multiple Sclerosis Exemplified by Fingolimod

Article • European Neurological Review, January 2015, Touch Digital Media, Ltd.

Professor Tjalf Ziemssen
Therapieziele und Therapiemanagement bei schubförmigremittierender Multipler Sklerose

Article • Nervenheilkunde, January 2015, Thieme Publishing Group

Professor Tjalf Ziemssen
Neuromuskuläre Erkrankungen

Article • January 2015, Springer Science + Business Media

Professor Tjalf Ziemssen
Erratum to: A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial

Article • Deutsche Zeitschrift für Nervenheilkunde, November 2014, Springer Science + Business Media

Professor Tjalf Ziemssen
Developmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination

Article • Molecular Psychiatry, November 2014, Nature

Professor Tjalf Ziemssen
Dendritic cells are specifically affected by different immunomodulatory treatment strategies in multiple sclerosis

Article • Journal of Neuroimmunology, October 2014, Elsevier

Professor Tjalf Ziemssen
Time matters – Acute stress response and glucocorticoid sensitivity in early multiple sclerosis

Article • Brain Behavior and Immunity, October 2014, Elsevier

Professor Tjalf Ziemssen
Accumulation and therapeutic modulation of 6-sulfo LacNAc + dendritic cells in multiple sclerosis

Article • Neurology Neuroimmunology & Neuroinflammation, September 2014, Wolters Kluwer Health

Professor Tjalf Ziemssen
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial

Article • Deutsche Zeitschrift für Nervenheilkunde, August 2014, Springer Science + Business Media

Professor Tjalf Ziemssen
Axon-Reflex-basierte Nervenmessverfahren in der Diagnostik autonomer Neuropathie

Article • Der Nervenarzt, July 2014, Springer Science + Business Media

Professor Tjalf Ziemssen
Time- and frequency-domain parameters of heart rate variability and sympathetic skin response in Parkinson’s disease

Article • Acta Neurovegetativa, July 2014, Springer Science + Business Media

Professor Tjalf Ziemssen
Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease

Article • BMC Neurology, June 2014, Springer Science + Business Media

Professor Tjalf Ziemssen
Attenuated brain-derived neurotrophic factor and hypertrophic remodelling: the SABPA study

Article • Journal of Human Hypertension, June 2014, Nature

Professor Tjalf Ziemssen, Professor Leoné Malan
MS disease activity in RESTORE

Article • Neurology, April 2014, Wolters Kluwer Health

Professor Tjalf Ziemssen
Effects of the PPARγ agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial

Article • Heart and Vessels, February 2014, Springer Science + Business Media

Professor Tjalf Ziemssen
Seasonal variation in plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma

Article • February 2014, Bioscientifica

Dr Christina Pamporaki, Professor Tjalf Ziemssen
Attenuated NOx responses and myocardial ischemia, a possible risk for structural vascular disease in African men: the SABPA study

Article • Journal of Human Hypertension, January 2014, Nature

Professor Tjalf Ziemssen, Professor Leoné Malan
Management of fingolimod in clinical practice

Article • Clinical Neurology and Neurosurgery, December 2013, Elsevier

Professor Tjalf Ziemssen
Perspectives of an innovative ophthalmological technology: Optical coherence tomography (OCT) – What should be of interest to the neurologist?

Article • Clinical Neurology and Neurosurgery, December 2013, Elsevier

Professor Tjalf Ziemssen
Nocturnal Blood Pressure, 3-Methoxy-4-hydroxyphenylglycol and Carotid Intima-media Thickness: The SABPA Study

Article • Heart Lung and Circulation, November 2013, Elsevier

Professor Leoné Malan, Professor Tjalf Ziemssen
MRI in acute cerebral ischemia of the young: The Stroke in Young Fabry Patients (sifap1) Study

Article • Neurology, November 2013, Wolters Kluwer Health

Dr Stefan Ropele, Prof. Dr. Otto W. Witte, Professor Tjalf Ziemssen
Das Herz in der Tintenfischfalle

Article • MMW - Fortschritte der Medizin, November 2013, Springer Science + Business Media

Professor Tjalf Ziemssen
Mehr als dokumentieren: computerunterstütztes Patientenmanagement

Article • DNP - Der Neurologe und Psychiater, October 2013, Springer Science + Business Media

Professor Tjalf Ziemssen
Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial

Article • Journal of Neurology Neurosurgery & Psychiatry, October 2013, BMJ

Professor Tjalf Ziemssen
Effects of Acute and Chronic Stress on the L-Arginine Nitric Oxide Pathway in Black and White South Africans

Article • Psychosomatic Medicine, October 2013, Wolters Kluwer Health

Professor Leoné Malan, Professor Tjalf Ziemssen
Defensive active coping facilitates chronic hyperglycaemia and endothelial dysfunction in African men: The SABPA study

Article • International Journal of Cardiology, September 2013, Elsevier

Professor Tjalf Ziemssen, Professor Leoné Malan
Therapeutic Decisions in Multiple Sclerosis

Article • JAMA Neurology, August 2013, American Medical Association (AMA)

Professor Tjalf Ziemssen
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

Article • The Lancet Neurology, August 2013, Elsevier

Professor Tjalf Ziemssen
Neuroborreliosis during natalizumab treatment in multiple sclerosis

Article • Neurology, July 2013, Wolters Kluwer Health

Professor Tjalf Ziemssen
Recent perspectives in neurology

Article • Acta Neurovegetativa, July 2013, Springer Science + Business Media

Professor Tjalf Ziemssen
Trigonometric regressive spectral analysis: an innovative tool for evaluating the autonomic nervous system

Article • Acta Neurovegetativa, June 2013, Springer Science + Business Media

Professor Tjalf Ziemssen
Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients

Article • Acta Neurovegetativa, June 2013, Springer Science + Business Media

Professor Tjalf Ziemssen
Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors

Article • Multiple Sclerosis Journal, May 2013, SAGE Publications

Professor Tjalf Ziemssen
Fingolimod — Sicherheitsdaten und Management in der klinischen Praxis

Article • DNP - Der Neurologe und Psychiater, May 2013, Springer Science + Business Media

Professor Tjalf Ziemssen
Cortisol Awakening Response Is Linked to Disease Course and Progression in Multiple Sclerosis

Article • PLOS One, April 2013, PLOS

Professor Tjalf Ziemssen
Defensive coping facilitates higher blood pressure and early sub-clinical structural vascular disease via alterations in heart rate variability: The SABPA study

Article • Atherosclerosis, April 2013, Elsevier

Professor Tjalf Ziemssen, Professor Leoné Malan
Chronisch krank und ohne Arbeit? Eine aktuelle Analyse zur Erwerbstätigkeit bei Multipler Sklerose

Article • Fortschritte der Neurologie · Psychiatrie, February 2013, Thieme Publishing Group

Professor Tjalf Ziemssen
Modern communication technology skills of patients with multiple sclerosis

Article • Multiple Sclerosis Journal, February 2013, SAGE Publications

Professor Tjalf Ziemssen
Lipoprotein apheresis of hypercholesterolemic patients mediates vasoprotective gene expression in human endothelial cells

Article • Atherosclerosis Supplements, January 2013, Elsevier

Professor Tjalf Ziemssen
Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients – an observational study

Article • Experimental & Translational Stroke Medicine, January 2013, Springer Science + Business Media

Professor Tjalf Ziemssen
The sensory channel of presentation alters subjective ratings and autonomic responses toward disgusting stimuli—Blood pressure, heart rate and skin conductance in response to visual, auditory, haptic and olfactory presented disgusting stimuli

Article • Frontiers in Human Neuroscience, January 2013, Frontiers

Professor Tjalf Ziemssen
Die Anwendung von Multi-Touch-Gesten in Patientenmanagementsystemen

Article • January 2013, Springer Science + Business Media

Professor Tjalf Ziemssen
Regular lipoprotein apheresis maintains residual cardiovascular and microvascular function in patients with advanced atherosclerotic disease

Article • Atherosclerosis Supplements, January 2013, Elsevier

Professor Tjalf Ziemssen
Metabolomic distinction of microvascular effects of lipoprotein apheresis – A pilot study

Article • Atherosclerosis Supplements, January 2013, Elsevier

Professor Tjalf Ziemssen
Neurovegetative Funktionsstörungen bei extrapyramidalmotorischen Erkrankungen

Article • Nervenheilkunde, January 2013, Thieme Publishing Group

Professor Tjalf Ziemssen
Greater cardiovascular reactivity to a cold stimulus is due to higher cold pain perception in black Africans

Article • Journal of Hypertension, December 2012, Wolters Kluwer Health

Professor Leoné Malan, Professor Tjalf Ziemssen
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

Article • The Lancet, November 2012, Elsevier

Dr David R Snydman, Professor Tjalf Ziemssen
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Article • The Lancet, November 2012, Elsevier

Dr David R Snydman, Professor Tjalf Ziemssen
Use and Acceptance of Electronic Communication by Patients With Multiple Sclerosis: A Multicenter Questionnaire Study

Article • Journal of Medical Internet Research, October 2012, JMIR Publications Inc.

Professor Tjalf Ziemssen
Wandel in aktueller Bewertung neuer Wirkstoffe erfordert Erhebung pharmakoökonomischer Daten: Behandlungszufriedenheit von Fingolimod (Gilenya) im Vergleich zu Erstlinientherapeutika bei Patienten mit Multipler Sklerose (PANGAEA und PEARL)

Article • Aktuelle Neurologie, September 2012, Thieme Publishing Group

Professor Tjalf Ziemssen
290 GREATER CARDIOVASCULAR REACTIVITY TO A COLD PRESSOR TEST IS DUE TO HIGHER COLD PAIN PERCEPTION IN BLACK AFRICANS

Article • Journal of Hypertension, September 2012, Wolters Kluwer Health

Professor Leoné Malan, Professor Tjalf Ziemssen
928 DEFENSIVE ACTIVE COPING FACILITATES CHRONIC HYPERGLYCEMIA AND EARLY VASCULAR STRUCTURAL CHANGES IN AFRICAN MEN

Article • Journal of Hypertension, September 2012, Wolters Kluwer Health

Professor Leoné Malan, Professor Tjalf Ziemssen
Psychoneuroimmunology - Psyche and Autoimmunity

Article • Current Pharmaceutical Design, August 2012, Bentham Science Publishers

Professor Tjalf Ziemssen
Neue Perspektiven eines modernen Untersuchungsverfahrens

Article • DNP - Der Neurologe und Psychiater, June 2012, Springer Science + Business Media

Professor Tjalf Ziemssen
Modernes Therapiemanagement zur Verbesserung der Therapie mit Interferon β-1b mit MSDS 3D

Article • Aktuelle Neurologie, May 2012, Thieme Publishing Group

Professor Tjalf Ziemssen
Identifying prodromal Parkinson's disease: Pre-Motor disorders in Parkinson's disease

Article • Movement Disorders, April 2012, Wiley

Professor Tjalf Ziemssen
Facilitated defensive coping, silent ischaemia and ECG left-ventricular hypertrophy

Article • Journal of Hypertension, March 2012, Wolters Kluwer Health

Professor Leoné Malan, Professor Tjalf Ziemssen
Improving patient&ndash;physician dialog: commentary on the results of the MS Choices survey

Article • Patient Preference and Adherence, February 2012, Taylor & Francis

Professor Tjalf Ziemssen, Prof Alessandra Lugaresi
Static posturography in aging and Parkinson's disease

Article • Frontiers in Aging Neuroscience, January 2012, Frontiers

Professor Tjalf Ziemssen
Brain activity increases blood pressure when stress perception is high

Article • Psychophysiology, December 2011, Wiley

Professor Leoné Malan, Professor Tjalf Ziemssen
Symptom management in patients with multiple sclerosis

Article • Journal of the Neurological Sciences, December 2011, Elsevier

Professor Tjalf Ziemssen
Cardiovascular autonomic testing in extrapyramidal disorders

Article • Journal of the Neurological Sciences, November 2011, Elsevier

Professor Tjalf Ziemssen
Circadian cortisol, depressive symptoms and neurological impairment in early multiple sclerosis

Article • Psychoneuroendocrinology, November 2011, Elsevier

Professor Tjalf Ziemssen
Multiple-Sklerose-Dokumentationssystem 3D

Article • Der Nervenarzt, October 2011, Springer Science + Business Media

Professor Tjalf Ziemssen
Seizures Associated with Zoledronic Acid for Osteoporosis

Article • The Journal of Clinical Endocrinology & Metabolism, July 2011, Endocrine Society

Professor Tjalf Ziemssen
Baroreceptor sensitivity, cardiovascular responses and ECG left ventricular hypertrophy in men: The SABPA study

Article • Blood Pressure, May 2011, Taylor & Francis

Professor Leoné Malan, Professor Tjalf Ziemssen
Treatment of dysautonomia in extrapyramidal disorders

Article • Deutsche Zeitschrift für Nervenheilkunde, May 2011, Springer Science + Business Media

Professor Tjalf Ziemssen
Seizures after treatment with zoledronic acid for osteoporosis

Article • Bone, May 2011, Elsevier

Professor Tjalf Ziemssen
Functional Energetics of CD4+-Cellular Immunity in Monoclonal Antibody-Associated Progressive Multifocal Leukoencephalopathy in Autoimmune Disorders

Article • PLOS One, April 2011, PLOS

Professor Tjalf Ziemssen
Determination of Baroreflex Sensitivity during the Modified Oxford Maneuver by Trigonometric Regressive Spectral Analysis

Article • PLOS One, March 2011, PLOS

Professor Tjalf Ziemssen
LDL apheresis improves deranged cardiovagal modulation in hypercholesterolemic patients

Article • Atherosclerosis, November 2010, Elsevier

Professor Tjalf Ziemssen
Rapidly progressive course of very late onset multiple sclerosis presenting with Parkinsonism: case report

Article • Multiple Sclerosis Journal, October 2010, SAGE Publications

Professor Tjalf Ziemssen
Psychoneuroimmunologische Aspekte des CIS

Article • Der Nervenarzt, October 2010, Springer Science + Business Media

Professor Tjalf Ziemssen
Considerations on discontinuing natalizumab for the treatment of multiple sclerosis

Article • Annals of Neurology, August 2010, Wiley

Professor Tjalf Ziemssen
Trigonometric Regressive Spectral Analysis Reliably Maps Dynamic Changes in Baroreflex Sensitivity and Autonomic Tone: The Effect of Gender and Age

Article • PLOS One, August 2010, PLOS

Professor Tjalf Ziemssen
Therapie autonomer Dysfunktion bei Patienten mit extrapyramidalen Erkrankungen

Article • Fortschritte der Neurologie · Psychiatrie, July 2010, Thieme Publishing Group

Professor Tjalf Ziemssen
Bevacizumab-induced changes in small arterial dilatation measured in vivo by dynamic retinal vessel analysis.

Article • Journal of Clinical Oncology, May 2010, American Society of Clinical Oncology (ASCO)

Professor Tjalf Ziemssen
The cold hand sign in multiple system atrophy: skin perfusion revisited

Article • Acta Neurovegetativa, February 2010, Springer Science + Business Media

Professor Tjalf Ziemssen
Cardiovascular autonomic dysfunction in Parkinson's disease

Article • Journal of the Neurological Sciences, February 2010, Elsevier

Professor Tjalf Ziemssen
CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function

Article • British Journal of Pharmacology, January 2010, Nature

Professor Tjalf Ziemssen
Autonomic Function and Cerebral Autoregulation in Patients Undergoing Carotid Endarterectomy

Article • Circulation Journal, January 2010, Japanese Circulation Society

Professor Tjalf Ziemssen
Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes

Article • Movement Disorders, December 2009, Wiley

Professor Tjalf Ziemssen
Ethnic‐specific Correlations of Visfatin With Circulating Markers of Endothelial Inflammation and Function

Article • Obesity, December 2009, Wiley

Professor Leoné Malan, Professor Tjalf Ziemssen
Retinal vessel analysis in hypercholesterolemic patients before and after LDL apheresis

Article • Atherosclerosis Supplements, December 2009, Elsevier

Professor Tjalf Ziemssen
Education Research: Cognitive performance is preserved in sleep-deprived neurology residents

Article • Neurology, November 2009, Wolters Kluwer Health

Professor Tjalf Ziemssen
Loss of nocturnal blood pressure fall in various extrapyramidal syndromes

Article • Movement Disorders, October 2009, Wiley

Professor Tjalf Ziemssen
Review: Treatment of dysautonomia in extrapyramidal disorders

Article • Therapeutic Advances in Neurological Disorders, October 2009, SAGE Publications

Professor Tjalf Ziemssen
Regulation of proteins mediating neurodegeneration in experimental autoimmune encephalomyelitis and multiple sclerosis

Article • PROTEOMICS - CLINICAL APPLICATIONS, October 2009, Wiley

Dr Giuseppina Maccarrone, Professor Tjalf Ziemssen
Comprehensive autonomic assessment does not differentiate between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy

Article • Acta Neurovegetativa, September 2009, Springer Science + Business Media

Professor Tjalf Ziemssen
Kostenanalyse neurologischer Patienten

Article • Der Nervenarzt, June 2009, Springer Science + Business Media

Professor Tjalf Ziemssen
Regulatorische T-Zellen bei Patienten mit Multipler Sklerose

Article • Der Nervenarzt, June 2009, Springer Science + Business Media

Professor Tjalf Ziemssen
Valsalva manoeuvre in patients with different Parkinsonian disorders

Article • Acta Neurovegetativa, June 2009, Springer Science + Business Media

Professor Tjalf Ziemssen
Pupillary responses to intranasal trigeminal and olfactory stimulation

Article • Acta Neurovegetativa, May 2009, Springer Science + Business Media

Professor Tjalf Ziemssen
Neurological disability, psychological distress, and health-related quality of life in MS patients within the first three years after diagnosis

Article • Multiple Sclerosis Journal, May 2009, SAGE Publications

Professor Tjalf Ziemssen
Effect of BEMER Magnetic Field Therapy on the Level of Fatigue in Patients with Multiple Sclerosis: A Randomized, Double-Blind Controlled Trial

Article • The Journal of Alternative and Complementary Medicine, May 2009, Mary Ann Liebert Inc

Professor Tjalf Ziemssen
Treatment strategies for nonmotor manifestations of Parkinson's disease

Article • Expert Opinion on Pharmacotherapy, April 2009, Informa Healthcare

Professor Tjalf Ziemssen
Multiple sclerosis beyond EDSS: depression and fatigue

Article • Journal of the Neurological Sciences, February 2009, Elsevier

Professor Tjalf Ziemssen
What can we learn from failed clinical trials in multiple sclerosis?

Article • Deutsche Zeitschrift für Nervenheilkunde, December 2008, Springer Science + Business Media

Professor Tjalf Ziemssen
Potential side effect of high-dose corticosteroid relapse treatment: acute generalized exanthematous pustulosis (AGEP)

Article • Multiple Sclerosis Journal, October 2008, SAGE Publications

Professor Tjalf Ziemssen
Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations

Article • Deutsche Zeitschrift für Nervenheilkunde, October 2008, Springer Science + Business Media

Professor Tjalf Ziemssen, Prof. Dr. Martin Schulz
Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes

Article • Acta Neurovegetativa, September 2008, Springer Science + Business Media

Professor Tjalf Ziemssen
Autonomic dysfunction in different subtypes of multiple system atrophy

Article • Movement Disorders, September 2008, Wiley

Professor Tjalf Ziemssen
Autonomic dysfunction in patients with progressive supranuclear palsy

Article • Movement Disorders, September 2008, Wiley

Professor Tjalf Ziemssen
Moderne Immuntherapie der multiplen Sklerose

Article • Aktuelle Neurologie, May 2008, Thieme Publishing Group

Professor Tjalf Ziemssen
Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study

Article • International Ophthalmology, April 2008, Springer Science + Business Media

Professor Tjalf Ziemssen
Influence of ECG Sampling Frequency on Spectral Analysis of RR Intervals and Baroreflex Sensitivity Using the EUROBAVAR Data set

Article • Journal of Clinical Monitoring and Computing, March 2008, Springer Science + Business Media

Professor Tjalf Ziemssen
Therapieadhärenz in der neurologischen Praxis

Article • Der Nervenarzt, March 2008, Springer Science + Business Media

Professor Tjalf Ziemssen
Erratum

Article • Deutsche Zeitschrift für Nervenheilkunde, February 2008, Springer Science + Business Media

Professor Tjalf Ziemssen
Review: Brain—immune communication psychoneuroimmunology of multiple sclerosis

Article • Multiple Sclerosis Journal, January 2008, SAGE Publications

Professor Tjalf Ziemssen
Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis

Article • Health and Quality of Life Outcomes, January 2008, Springer Science + Business Media

Professor Tjalf Ziemssen
Pharmacokinetic/Pharmacodynamic Modelling of Venlafaxine

Article • Clinical Pharmacokinetics, January 2008, Springer Science + Business Media

Professor Tjalf Ziemssen
The Effects of Venlafaxine on Autonomic Functions in Healthy Volunteers

Article • Journal of Clinical Psychopharmacology, December 2007, Wolters Kluwer Health

Professor Tjalf Ziemssen
Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes

Article • Movement Disorders, October 2007, Wiley

Professor Tjalf Ziemssen
Non-motor dysfunction in Parkinson's disease

Article • Parkinsonism & Related Disorders, August 2007, Elsevier

Professor Tjalf Ziemssen
Glatiramer acetate: Mechanisms of action in multiple sclerosis

Article • Autoimmunity Reviews, August 2007, Elsevier

Professor Tjalf Ziemssen
Intravitreous bevacizumab and blood pressure: does ‘safe’ mean ‘safe enough’?

Article • Acta Ophthalmologica Scandinavica, August 2007, Wiley

Professor Tjalf Ziemssen
A New Line Immunoassay for the Multiparametric Detection of Antiganglioside Autoantibodies in Patients with Autoimmune Peripheral Neuropathies

Article • Annals of the New York Academy of Sciences, August 2007, Wiley

Professor Tjalf Ziemssen
Psychoneuroimmunology – Cross-talk between the immune and nervous systems

Article • Deutsche Zeitschrift für Nervenheilkunde, May 2007, Springer Science + Business Media

Professor Tjalf Ziemssen
Intravitreous bevacizumab and blood pressure: does ‘safe’ mean ‘safe enough’?

Article • Acta Ophthalmologica Scandinavica, April 2007, Wiley

Professor Tjalf Ziemssen
The effects of lorazepam on skin conductance responses to aversive stimuli in healthy subjects

Article • Clinical Autonomic Research, March 2007, Springer Science + Business Media

Professor Tjalf Ziemssen
Stroke-Induced Immunodepression: Experimental Evidence and Clinical Relevance

Article • Stroke, January 2007, Wolters Kluwer Health

Professor Tjalf Ziemssen
Glatiramer Acetate: Mechanisms of Action in Multiple Sclerosis

Article • January 2007, Elsevier

Professor Tjalf Ziemssen
Autonome Dysfunktion beim idiopathischen Parkinson-Syndrom und der Multisystematrophie

Article • Aktuelle Neurologie, September 2006, Thieme Publishing Group

Professor Tjalf Ziemssen
Multiple Sklerose

Article • Der Ophthalmologe, July 2006, Springer Science + Business Media

Professor Tjalf Ziemssen
Untersuchung zur Genauigkeit der Abtastung von EKG-Signalen für eine nachfolgende Spektralanalyse kontinuierlich gemessener RR-Intervalle im Schlaflabor

Article • Somnologie - Schlafforschung und Schlafmedizin, May 2006, Springer Science + Business Media

Professor Tjalf Ziemssen
Untersuchung zur Genauigkeit der Abtastung von EKG-Signalen fur eine nachfolgende Spektralanalyse kontinuierlich gemessener RR-Intervalle im Schlaflabor. Assessment of Accuracy of ECG Signal Sampling for Spectral Analysis of Beat-to-Beat Recorded R-R I...

Article • Somnologie - Schlafforschung und Schlafmedizin, May 2006, Springer Science + Business Media

Professor Tjalf Ziemssen
Multiple sclerosis and the autonomic nervous system

Article • Deutsche Zeitschrift für Nervenheilkunde, February 2006, Springer Science + Business Media

Professor Tjalf Ziemssen
Pandysautonomie als Erstmanifestation eines Plasmozytoms

Article • Aktuelle Neurologie, January 2006, Thieme Publishing Group

Professor Tjalf Ziemssen
Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis

Article • Deutsche Zeitschrift für Nervenheilkunde, October 2005, Springer Science + Business Media

Professor Tjalf Ziemssen
The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE)

Article • Autoimmunity Reviews, September 2005, Elsevier

Professor Tjalf Ziemssen
Autoimmune CD4+ T Cell Memory: Lifelong Persistence of Encephalitogenic T Cell Clones in Healthy Immune Repertoires

Article • The Journal of Immunology, June 2005, The American Association of Immunologists

Professor Tjalf Ziemssen
Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy

Article • Journal of the Neurological Sciences, June 2005, Elsevier

Professor Tjalf Ziemssen
Autonome Störungen

Article • January 2005, Elsevier

Professor Tjalf Ziemssen
The Activation Status of Neuroantigen-specific T Cells in the Target Organ Determines the Clinical Outcome of Autoimmune Encephalomyelitis

Article • Journal of Experimental Medicine, January 2004, Rockefeller University Press

Professor Tjalf Ziemssen
Neuroprotection and Glatiramer Acetate: The Possible Role in the Treatment of Multiple Sclerosis

Article • January 2004, Springer Science + Business Media

Professor Tjalf Ziemssen
Adult polyglucosan body disease: A postmortem correlation study

Article • Neurology, July 2003, Wolters Kluwer Health

Professor Tjalf Ziemssen
Morbus Parkinson — Gehirnerkrankung oder Ganzkörpererkrankung?

Article • January 2003, Springer Science + Business Media

Professor Tjalf Ziemssen
Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy

Article • Brain, November 2002, Oxford University Press (OUP)

Professor Tjalf Ziemssen
Behandlung der Multiplen Sklerose mit Glatiramer-Azetat

Article • Der Nervenarzt, April 2002, Springer Science + Business Media

Professor Tjalf Ziemssen
Graves’ disease after treatment with Alemtuzumab for multiple sclerosis

Article • HORMONES, February 2002, Hellenic Endocrine Society

Professor Tjalf Ziemssen
Phospholipase A2 degradation products modulate epithelial and stromal 5?-reductase activity of human benign prostatic hyperplasia in vitro

Article • The Prostate, December 2001, Wiley

Professor Tjalf Ziemssen
In vitro modulation of steroid 5α-reductase activity by phospholipases in epithelium and stroma of human benign prostatic hyperplasia

Article • Steroids, June 2001, Elsevier

Professor Tjalf Ziemssen
Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis

Article • Drug Safety, January 2001, Springer Science + Business Media

Professor Tjalf Ziemssen
Posttranslationale Regulationsmöglichkeiten membrangebundener Enzyme am Beispiel der prostatischen 5α-Reduktase

Article • LaboratoriumsMedizin, January 1999, De Gruyter

Professor Tjalf Ziemssen

Search Kudos

Main menu

Discover

Subjects on Kudos

Services and resources

Admin

All Stories